

We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.



*This copy is for your personal, non-commercial use. Please do not redistribute without permission.*

Printed By

# Stonehaven Incubate targets pet antimicrobials in latest project

18 Dec 2018 | **NEWS**

by **Joseph Harvey** | @JHJournalist | joseph.harvey@informa.com

Stonehaven Incubate has partnered with antimicrobial protein specialist Lysando to develop therapies for companion animal infections.



The partners will conduct proof-of-concept trials for topical treatments based on Lysando's Artilysin protein-based antimicrobials.

Following completion of the studies, a new company will be formed with exclusive rights to manufacture, develop and commercialize the new treatments for skin, eye and ear infections in dogs.

Artilysin molecules selectively attack the cell wall of bacteria. This leads to cell death caused by high osmotic pressure.

Dr Martin Griessl, co-chief executive of Lysando, said: "The Artilysin platform is very exciting because it avoids many of the problems that are threatening to limit the future use of standard antibiotics. Artilysins are not antibiotics – their mode of action is based on laws of physics and does not interfere with the bacterial metabolism."

## **Animal Pharm Podcast #9: Mark Heffernan explains Stonehaven Incubate's game plan**

By Joseph Harvey

15 Mar 2018

Markus Count Matuschka de Greiffenclau, founder of Lysando, added: "Artilysin proteins can be designed to target specific pathogens whilst preserving the host's natural microbiome, thus supporting the natural healing process and reducing side effects. Importantly, there is no evidence that pathogens can become immune to their action."

*Stonehaven Incubate has been launched to translate innovation in the human health space into new animal health companies. Animal Pharm Joseph Harvey editor spoke to the firm's chief executive Mark Heffernan about this new home for start-ups.*

[Read the full article here >](#)

Based in Liechtenstein, Lysando was founded in 2009. The company has developed 450 functional Artilysins. According to the company, fast-acting and non-toxic Artilysins provide benefits over antibiotics by: offering low resistance potential; killing only targeted bacteria; having no impact on the immune system; being rapidly biodegradable; treating chronic bacterial infections; working in biofilms; and causing limited side effects.

According to Lysando, "a balanced bacterial flora is the prerequisite for a robust animal health". This plays into the credo of Stonehaven Incubate's first portfolio company, [Anizome](#), which was installed earlier this year. Anizome is focused on developing a commercial therapeutic microbiome discovery platform dedicated to animal health and nutrition

In recent months, Stonehaven Incubate has sealed its [first fundraising](#) and added an [investment manager](#). The incubator was [founded this year](#). It aims to bring innovation from human health to the veterinary medicines space that would otherwise not cross over between industries. This scope spans biotechnology, pharmaceuticals, data and devices.